## Massimo Primignani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7941474/publications.pdf

Version: 2024-02-01

159358 143772 5,189 61 30 57 citations h-index g-index papers 62 62 62 3795 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology, 2005, 41, 553-558.	3.6	617
2	An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis. Gastroenterology, 2009, 137, 2105-2111.	0.6	472
3	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010, 51, 210-218.	3.6	458
4	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. Annals of Internal Medicine, 2009, 151, 167.	2.0	422
5	Thrombin generation in patients with cirrhosis: The role of platelets. Hepatology, 2006, 44, 440-445.	3.6	347
6	Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 2006, 44, 1528-1534.	3.6	249
7	Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology, 2005, 41, 603-608.	3.6	190
8	The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology, 2007, 46, 520-527.	3.6	179
9	Antithrombotic treatment with directâ€acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	1.9	178
10	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	1.8	149
11	Changing Concepts of Cirrhotic Coagulopathy. American Journal of Gastroenterology, 2017, 112, 274-281.	0.2	149
12	Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. Journal of Hepatology, 2013, 59, 265-270.	1.8	146
13	Preemptive‶IPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	3.6	144
14	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology, 2010, 52, 249-255.	3.6	123
15	Portal vein thrombosis, revisited. Digestive and Liver Disease, 2010, 42, 163-170.	0.4	119
16	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	1.8	112
17	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver International, 2013, 33, 362-367.	1.9	107
18	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Internal and Emergency Medicine, 2012, 7, 139-144.	1.0	96

#	Article	IF	CITATIONS
19	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. Hepatology, 2020, 71, 658-669.	3.6	95
20	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1146-1152.e4.	2.4	77
21	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. Journal of Hepatology, 2015, 63, 1118-1125.	1.8	74
22	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. Journal of Hepatology, 2009, 50, 916-922.	1.8	69
23	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	<b>57</b>
24	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	2.0	53
25	Resistance to thrombomodulin is associated with <i>de novo</i> portal vein thrombosis and low survival in patients with cirrhosis. Liver International, 2016, 36, 1322-1330.	1.9	51
26	The Role of Thrombophilia in Splanchnic Vein Thrombosis. Seminars in Liver Disease, 2008, 28, 293-301.	1.8	47
27	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	2.4	42
28	Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Digestive and Liver Disease, 2014, 46, 152-156.	0.4	38
29	Plasma miRNAâ€based signatures in CRC screening programs. International Journal of Cancer, 2020, 146, 1164-1173.	2.3	35
30	MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood, 2008, 111, 4418-4418.	0.6	30
31	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	1.8	28
32	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. Journal of Hepatology, 2009, 51, 288-295.	1.8	26
33	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Digestive and Liver Disease, 2016, 48, 1208-1213.	0.4	20
34	Evaluation of three "beyond Baveno Vl―criteria to safely spare endoscopies in compensated advanced chronic liver disease. Digestive and Liver Disease, 2019, 51, 1135-1140.	0.4	18
35	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leukemia Research, 2015, 39, 525-529.	0.4	17
36	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterology Journal, 2016, 4, 363-370.	1.6	16

#	Article	IF	CITATIONS
37	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines, 2022, 10, 249.	1.4	16
38	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. Journal of Hepatology, 2021, 75, 1355-1366.	1.8	15
39	Incidence and mortality of renal dysfunction in cirrhotic patients with acute gastrointestinal bleeding: a systematic review and meta-analysis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1181-1188.	1.4	13
40	Nonselective Î <sup>2</sup> -Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study. Advances in Therapy, 2020, 37, 1452-1463.	1.3	12
41	Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal P-Blocker Therapy. American Journal of Gastroenterology, 2021, 116, 1342-1344.	0.2	12
42	Blood Bacterial DNA Load and Profiling Differ in Colorectal Cancer Patients Compared to Tumor-Free Controls. Cancers, 2021, 13, 6363.	1.7	12
43	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. Journal of Thrombosis and Thrombolysis, 2019, 48, 52-60.	1.0	8
44	Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2021, 33, e423-e430.	0.8	8
45	Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clinical and Translational Gastroenterology, 2021, 12, e00409.	1.3	8
46	Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm. Acta Haematologica, 2022, 145, 30-37.	0.7	7
47	Association of portal venous system thrombosis with endoscopic variceal treatment: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2021, 32, 125-131.	0.8	6
48	Diagnosis of thrombophilia/prothrombotic conditions in patients with liver disease. Clinical Liver Disease, 2014, 3, 126-128.	1.0	4
49	Assessing spleen stiffness by point shearâ€wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension?. GastroHep, 2019, 1, 205-213.	0.3	3
50	ABO, von Willebrand factor/factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?. Liver International, 2020, 40, 1788-1789.	1.9	3
51	Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded?. Digestive and Liver Disease, 2021, 53, 1394-1395.	0.4	3
52	Letter to the Editor: Thromboelastographyâ€Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?. Hepatology, 2020, 72, 1158-1159.	3.6	2
53	Pancreatitisâ€related splanchnic vein thrombosis: What role, what warnings for anticoagulation therapy?. Journal of Digestive Diseases, 2021, 22, 122-125.	0.7	2
54	Direct oral anticoagulants for portal vein thrombosis in cirrhosis: Good news from meta-analysis?. Digestive and Liver Disease, 2022, 54, 54-55.	0.4	2

#	Article	IF	CITATIONS
55	Reply:. Hepatology, 2007, 45, 832-833.	3.6	1
56	Endoscopy in acute variceal bleeding: Not always the sooner, the better? Digestive and Liver Disease, 2019, 51, 999-1000.	0.4	1
57	High-dose pre-endoscopic intravenous proton pump inhibitors in upper gastrointestinal bleeding: Utility or futility?. Digestive and Liver Disease, 2021, 53, 387-388.	0.4	1
58	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 798-799.	2.4	0
59	Etiology of non-cirrhotic portal vein thrombosis in children: Few or many causes?. Digestive and Liver Disease, 2020, 52, 118-120.	0.4	0
60	Combined approach for embolization of otherwise unmanageable gastric varices. Annals of Gastroenterology, 2021, 34, 510-515.	0.4	0
61	Post-banding ulcer bleeding in the elective setting: Are there any risk factors?. Digestive and Liver Disease, 2021, 53, 658-660.	0.4	0